PROGNOSTIC VALUE OF TUMOR NECROSIS FACTOR-ALPHA IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
https://doi.org/10.15789/1563-0625-2016-5-489-494
Abstract
The prognostic value of tumor necrosis factor-alfa (TNFα), a pro-inflammatory cytokine was studied in 140 patients with a newly diagnosed chronic lymphocytic leukemia (CLL). TNFα contents in blood serum was determined using ELISA method. A significant increase of serum TNFα was shown in patients with newly diagnosed CLL, as compared to healthy individuals. Dependence of the cytokine concentration on clnical stage and course of disease was revealed: the highest levels of serum TNFα were registered in patients with advanced disease and/or CLL progression. Distinct correlations were revealed between the studied cytokine amounts and clinical laboratory parameters reflecting the cell proliferative activity and tumor clone size. Immunochemotherapy was accompanied by a significant reduction of TNFα levels. According to the data from multivariate regression analysis. TNFα level of at the time of the diagnosis was an independent predictor of overall survival. Hence, TNFα plays an important role in CLL pathogenesis and may be used as an additional predictive factor for CLL outcomes.
About the Authors
E. N. Zotina
Kirov Research Institute of Hematology and Blood Transfusion
Russian Federation
Russian Federation
PhD (Medicine), Junior Research Associate, Clinical Research Department,
610027, Kirov, Krasnoarmeyskaya str., 72
T. P. Zagoskina
Kirov State Medical Academy
Russian Federation
Russian Federation
PhD (Medicine), Associate Professor, Department of Hospital Therapy,
Kirov
V. I. Shardakov
Kirov Research Institute of Hematology and Blood Transfusion
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, Head, Laboratory of Leukemia Immunology,
Kirov
A. V. Yovdy
Kirov Research Institute of Hematology and Blood Transfusion
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, Head, Laboratory of Leukemia Immunology,
Kirov
G. A. Zaitseva
Kirov Research Institute of Hematology and Blood Transfusion
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, Head of Research Direction,
Kirov
References
1. Жевак Т.Н., Чеснокова Н.П., Шелехова Т.В. Закономерности изменений цитокинового статуса при хроническом лимфолейкозе и их роль в патогенезе прогрессирующих форм заболевания // Саратовский научно-медицинский журнал, 2012. Т. 8, № 2. С. 203-209. [Zhevak T.N., Chesnokova N.P., Schelekhova T.V. [Regularities of cytokine status changes in chronic lymphocytic leukaemia and their role in pathogenesis forms of disease. Saratovskiy nauchno-meditsinskiy zhurnal = Saratov Journal of Medical Scientific Research, 2012, Vol. 8, no 2, pp. 203-209. (In Russ.)]
2. Кетлинский С.А., Симбирцев А.С. Цитокины. СПб.: Фолиант, 2008. 552 с. [Ketlinsky S.A., Simbirtsev A.S. Cytokines]. St. Petersburg: Foliant, 2008. 552 p.
3. Волкова М.А. Клиническая онкогематология. М.: Медицина, 2007. 1120 с. [Volkova M.A. Clinical Oncohematology]. Moscow: Medicine, 2007. 1120 p.
4. Balkwill F., Joffroy C. TNF: a tumor-suppressing factor or tumor-promoting factor? Future Oncology, 2010, Vol. 6, no. 12, pp. 1833-1836.
5. Bojarska-Junak A., Hus I., Szczepanek E.W., Dmoszynska A., Rolinski J. Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leukemia Research, 2008, Vol. 32, no 2, рр. 225-233.
6. Ferrajoli A., Keating M.J., Manshouri T., Giles F.J., Dey A., Estrov Z., Koller C.A., Kurzrock R., Thomas D.A., Faderl S., Lerner S., O'Brien S., Albitar M. The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia. Blood, 2002, Vol. 100, no. 4, pp. 1215-1219.
7. Hallek M., Cheson B.D., Catovsky D., Caligaris F., Dighiero G., Dohner H., Hillmen P., Keating M.J., Montserrat E., Rai K.R., Kipps T.J., International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 2008, Vol. 111, no 12, pp. 5446-5456.
8. Klein U., Dalla-Favera R. New insights into the pathogenesis of chronic lymphocytic leukemia. Seminars in Cancer Biology, 2010, Vol. 20, no. 6, pp. 377-338.
9. Singer M.K., Assem M., Abdel Ghaffar A.B., Morcos N.Y. Role of TNF-alpha as a survival prognostic marker in chronic lymphocytic leukemia patients. The Egyptian Journal of Immunology, 2011, Vol. 18, no. 2, pp. 51-60.
Review
For citations:
Zotina E.N., Zagoskina T.P., Shardakov V.I., Yovdy A.V., Zaitseva G.A. PROGNOSTIC VALUE OF TUMOR NECROSIS FACTOR-ALPHA IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Medical Immunology (Russia). 2016;18(5):489-494. (In Russ.) https://doi.org/10.15789/1563-0625-2016-5-489-494
Views:
879
Email this article 